Congenital Adrenal Hyperplasia: The Lancet Seminar Series by El-Maouche, Diala et al.
 
 
University of Birmingham
Congenital Adrenal Hyperplasia: The Lancet
Seminar Series
El-Maouche, Diala; Arlt, Wiebke; Merke, Deborah P
DOI:
10.1016/S0140-6736(17)31431-9
License:
Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)
Document Version
Peer reviewed version
Citation for published version (Harvard):
El-Maouche, D, Arlt, W & Merke, DP 2017, 'Congenital Adrenal Hyperplasia: The Lancet Seminar Series', The
Lancet. https://doi.org/10.1016/S0140-6736(17)31431-9
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Checked 1/6/2017
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
 
 
1 
Congenital Adrenal Hyperplasia: The Lancet 
Seminar Series 
 
Diala El-Maouche1, MD, MS, Wiebke Arlt2, MD, DSc, FRCP, Deborah P. 
Merke1,3, MD, MS 
 
1National Institutes of Health Clinical Center, Bethesda, Maryland, USA 20892; 
2Institute of Metabolism and Systems Research (IMSR), University of Birmingham 
& Centre for Endocrinology, Diabetes and Metabolism (CEDAM), Birmingham 
Health Partners, Birmingham, UK; 3The Eunice Kennedy Shriver National Institute 
of Child Health and Human Development, Bethesda, Maryland, USA 20892. 
 
Corresponding author: 
Dr. Deborah P. Merke 
10 Center Drive, Room 1-2740 
Bethesda, MD 20892-1932 
Email: DMerke@ nih.gov 
 
  
Manuscript
 
 
2 
Search Strategy and Selection Criteria: 
We searched the Cochrane Library (January 2010-Septmeber 2016), MEDLINE (January 2010-
Septmeber 2016), and EMBASE (January 2010-Septmeber 2016). Keywords and controlled 
vocabulary and their synonyms were used when appropriate. We used variations of the search 
term “congenital adrenal hyperplasia” in combination with the terms “diagnosis/diagnostics”, 
“genetics”, “genomics”, “adrenal crisis”, “glucocorticoid”, “mineralocorticoid”, “gene therapy”, 
“quality of life”, “well-being”, “screening”, “metabolomics”, “prenatal”, “antenatal”, “bone 
mineral density”, “tumor”, “pregnancy”, “treatment/therapy/ therapeutic”, 
“fertility/fecundity”, “surgery”, “management”, “metabolic”, “complications”. We largely 
selected publications in the past 5 years, but did not exclude commonly referenced and highly 
regarded older publications. We also searched the reference lists of articles identified by this 
search strategy and selected those we judged relevant. Review articles and book chapters are 
cited to provide readers with more details and more references than this Seminar has room for.  
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Introduction 
In 1865, Luigi De Crecchio, an Italian pathologist, described the life of a male, whose autopsy 
revealed female internal anatomy and large adrenal glands, representing the first known case 
of presumed congenital adrenal hyperplasia (CAH)1 (Figure 1). However, treatment for CAH was 
not introduced until almost a century later when cortisone was given for what was then known 
as the adrenogenital syndrome.17-19 
 CAH comprises a group of seven autosomal recessive diseases caused by a defect in any one 
of the several steps leading to cortisol biosynthesis: 21-hydroxylase (21OH), 11β-hydroxylase 
(11βOH), 17α-hydroxylase/ 17,20-lyase (17OH), 3β-hydroxysteroid dehydrogenase type 2 
(3βHSD2), steroidogenic acute regulatory protein (StAR), P450 cholesterol side-chain cleavage 
enzyme (SCC), and P450 Oxidoreductase (POR). The pathophysiology and genetics of the 
various types of CAH have been elucidated in the past 50 years. Multiple hormonal imbalances 
occur and CAH manifests with a range of severity clinically and biochemically, with or without 
alterations in glucocorticoid, mineralocorticoid, and sex steroid production. Both severe 
(classic) and mild (nonclassic) forms have been described.     
Over 95% of CAH is due to 21OH deficiency,20 characterized by impaired cortisol and 
aldosterone production and androgen excess.   Life-saving neonatal screening for classic CAH 
due to 21OH deficiency was first performed in Alaska in 19777 and is currently being carried out 
worldwide in over 40 countries, including all 50 US states since 2009, though not yet 
implemented in the UK.7,20-22 Although all types of classic CAH are rare orphan diseases, the 
nonclassic form of 21OH deficiency is estimated to be one of the most common autosomal 
recessive disorders.23 
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Despite these advances, CAH remains one of the most challenging endocrine disorders to 
diagnose, manage and treat because of the direct and indirect effects on steroidogenic 
pathways and the rarity of these conditions.  Advances in genetics, metabolomics and 
treatment strategies continue to improve our understanding of these complex diseases and aim 
to improve patient outcome. Following is an overview of these complex disorders.  
 
Genetics and Pathophysiology of the Various Forms of CAH 
All types of CAH are monogenetic and autosomal recessive.  Most patients are compound 
heterozygotes, meaning they have different mutations in the two alleles. The clinical 
manifestation follows the less severely mutated allele, and, in general, there is good genotype-
phenotype correlation.24,25 
Adrenal steroidogenesis occurs by a series of steps facilitated by the zone specific enzyme 
expression and different types of CAH interrupt this process at distinct branchpoints.  In 
addition to the classical well-established steroidogenesis pathway, an alternative pathway to 
active androgen biosynthesis exists (termed “backdoor” pathway),26,27 which may play a role in 
the pathophysiology of CAH (Figure 2A). The clinical manifestation of CAH is closely related to 
the type and severity of the impairment.  
 
21-hydroxylase (21OH) deficiency  
The gene for 21OH, CYP21A2, is located within the human leukocyte antigen class III region of 
chromosome 6 (Table 1). CYP21A2 and a homologous pseudogene, CYP21A1P, lie 
approximately 30 kb apart.   Meiotic recombination events are common in this genomic region 
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because of the high degree of sequence homology between duplicated genes.  Approximately 
95% of CYP21A2 disease causing mutations are CYP21A1P derived variants or deletions due to 
recombination events.24,35 
Defective 21-hydroxylation results in elevated precursors, most notably 17-
hydroxyprogesterone (17OHP), which is used for diagnosis, and decreased glucocorticoid and 
mineralocorticoid synthesis (Figure 2B).  ACTH-stimulated androgen production occurs because 
there is no block in the pathway leading to adrenal androgens.  
Conventionally, classic 21OH deficiency is subclassified into salt-wasting (SW) and simple 
virilizing (SV) forms, reflecting the severity of aldosterone deficiency.  Mutations which 
completely inactivate CYP21A2 result in the SW phenotype, which, without neonatal screening, 
presents in the first 2 weeks of life with a life-threatening adrenal crisis (Table 2).20 Patients 
with classic SV CAH have mutations that retain 1-2 % of 21OH activity, and minimal aldosterone 
production prevents a neonatal crisis.  Excess fetal adrenal androgen exposure results in 
virilization of the external genitalia of 46,XX classic patients (SW and SV) (Figure 3A). Without 
neonatal screening, SV males are diagnosed as toddlers with signs and symptoms of androgen 
excess. Postnatal excess androgen leads to premature pubic hair and rapid skeletal growth. 
Patients with the nonclassic form retain up to 50 percent of enzyme activity and mostly do not 
have adrenal insufficiency, but may have partial glucocorticoid deficiency, and female genitalia 
are normal. Patients may present with mild androgen excess or have little or no symptoms. In 
fact, the term cryptic CAH was coined to define patients with nonclassic CAH who are identified 
by family genetic studies, but are otherwise asymptomatic.36  
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11-hydroxylase (11βOH) deficiency  
CAH due to 11βOH deficiency is due to CYP11B1 mutations (Table 1).  CYP11B1 functions in the 
zona fasciculate to convert 11-deoxycortisol to cortisol and deoxycorticosterone (DOC) to 
corticosterone, under ACTH regulation (Figure 2C). The majority of CYP11B1 mutations 
correspond to minimal or absent enzyme activity resulting in a classic phenotype.37  
Impaired 11-hydroxylation results in decreased corticosterone and cortisol synthesis, with 
subsequent increase in ACTH and excess androgens, because of shunting of the pathway 
towards androgen production. Normally corticosterone and DOC production by CYP11B1 
transcription in the adrenal zona fasciculata is minimal, but DOC levels can rise dramatically 
under the influence of ACTH.38 DOC is a weak mineralocorticoid, however elevated DOC 
suppresses the renin-angiotensin system and results in extracellular fluid volume expansion, 
hypertension, low plasma renin activity and low aldosterone levels, although the ability to 
produce aldosterone remains. These effects may not occur in the neonatal period due to the 
renal mineralocorticoid resistance that is present in the first few months of life.  Clinically, 
patients present similar to 21OH deficiency, with signs of androgen excess, but also have 
hypertension rather than salt loss (Table 2).28 A nonclassic form of CYP11B1 deficiency exists 
but is very rare.39  
 
17α-hydroxylase/ 17,20-lyase (17OH) deficiency  
The CYP17A1 gene encodes an enzyme that expresses both 17α-OH and 17,20-lyase activities 
(Table 1). Due to its location in the steroidogenic pathway, severe mutations impair adrenal and 
gonadal sex steroid production (Figure 2D), which causes sexual infantilism and pubertal failure 
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(Table 2).31 There is a block in DHEA production, which prevents adrenarche and the 
development of pubic and axillary hair.  CYP17A1 is expressed in the zona fasciculate and zona 
reticularis, not in the zona glomerulosa.  Therefore, ACTH-mediated steroidogenesis results in 
elevated DOC and corticosterone. High levels of DOC cause sodium retention, hypertension and 
hypokalemia, with suppression of aldosterone production. Corticosterone, which has 
glucocorticoid activity, prevents adrenal crisis, although cortisol production is low or absent. 
Both 46,XX and 46,XY patients have female external genitalia, and usually present during 
puberty as females with lack of secondary sexual characteristics, hypergonadotropic 
hypogonadism and low-renin hypertension (Table 2).  Isolated 17,20-lyase- deficiency has been 
reported40 but is extremely rare and in truly isolated form is caused by mutations in 
cytochrome b5 (CYB5A), the co-factor needed by CYP17A1 to exert 17,20 lyase activity.41 
Although phenotype variability occurs, a nonclassic form with subtle clinical manifestations has 
not been defined. 
 
3β-hydroxysteroid dehydrogenase type 2 (3βHSD2) deficiency  
3β-hydroxysteroid dehydrogenase exists in two isoforms, type 1 (3βHSD1) and type 2 (3βHSD2), 
encoded by HSD3B1 and HSD3B2 respectively (Table 1). HSD3B2 is highly expressed in the 
adrenals and gonads, while HSD3B1 is expressed in the placenta and peripheral tissues.  
Impaired 3βHSD2 results in decreased aldosterone, cortisol, and androstenedione, with a 
subsequent increase in renin, ACTH, and DHEA (Figure 2E). DHEA can be converted to 
testosterone by extraadrenal 3βHSD1. Patients present in infancy with a salt-wasting adrenal 
crisis, underdeveloped 46,XY genitalia and rarely 46,XX virilization (Table 2).  
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The hormonal criteria for diagnosing 3βHSD2 deficiency has changed over the past three 
decades because the initial studies identifying a possible nonclassic form were not based on 
genetic findings and subsequent genetic studies failed to confirm the diagnosis.42-44 Nonclassic 
3βHSD2 deficiency exists, but is extremely rare. 
 
P450 Oxidoreductase (POR) deficiency  
POR plays a key role in the electron transport that occurs in the endoplasmic reticulum and 
several enzymes, including 17OH, 21OHD, and aromatase, depend on POR for their catalytic 
activity (Figure 2F). The discovery of POR deficiency in 200415,16 provided an explanation for 
multiple hormonal deficiency initially known as apparent combined 17OH and 21OH deficiency. 
Lack of placental aromatization of fetal androgens could contribute to the virilization observed 
in some mothers carrying affected babies.  However, the production of androgens via an 
alternative pathway to the most potent androgen, non-aromatizable 5-dihydrotestosterone 
(DHT), may also explain the prenatal virilization of affected females, while postnatally affected 
individuals invariable display sex steroid deficiency.16 POR also acts also as an electron donor to 
cytochrome P450 (CYP) enzymes other than steroidogenic CYP enzymes, explaining POR 
deficiency-associated changes in drug metabolism45 and the pathogenesis of the often 
observed skeletal dysplasia.46  
Most POR mutations retain some enzymatic function; homozygous mutations with complete 
loss of function may not be viable, as seen in rodent models.47 Presentation varies from mildly 
affected adults with amenorrhea and polycystic ovaries (females) or androgen deficiency 
(males), to severe hormone disturbances causing atypical genitalia in both 46,XX and 46,XY 
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(Table 1, 2). 46,XX virilization does not progress, and patients postnatally have sex steroid 
deficiency. Craniosynostosis, radioulnar or radiohumeral synostosis, midface hypoplasia, and 
other skeletal manifestations resembling the Antley-Bixler syndrome may occur.  
  Generally, POR deficient patients do not have mineralocorticoid deficiency as 
impairment of 17-hydroxylase increases mineralocorticoid intermediates, and affected adults 
may develop hypertension. Patients have variable cortisol response to cosyntropin testing, with 
most patients requiring either permanent or stress dose glucocorticoid coverage.32  
 
Lipoid CAH 
Classic lipoid CAH is characterized by deficiency of all steroid hormones and is due to StAR 
mutations (Table 1, Figure 2G). StAR regulates the transfer of cholesterol from the outer to the 
inner mitochondrial membrane, a key step in steroidogenesis initiation.  When cholesterol 
cannot be mobilized, adrenal lipid droplets accumulate and are seen on autopsy, thus the name 
lipoid CAH.  Lipoid CAH is one of rarest forms of CAH, resulting in neonatal crisis, and both 
46,XX and 46,XY infants have female external genitalia (Table 2).48 Later presentation up to one 
year of age has been described.49  
The pathogenesis of lipoid CAH is explained by a two-hit model: first, loss of StAR leads to 
the accumulation of intracellular cholesterol and cholesterol esters, and the second hit arises 
from destruction of the cellular function by the accumulated products.48,50,51 This mechanism 
explains some unusual phenotype.  Spontaneous puberty has been described in 46,XX  patients, 
because of minimal ovarian StAR expression.48 The ovaries are quiescent during fetal life and 
childhood and therefore toxic accumulation of cholesterol can be delayed until adolescence.  
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A nonclassic form was first described in 200652 associated with mutations that retain 
approximately 20-30% of StAR activity. Most of these cases were initially misdiagnosed as 
Addison’s disease or isolated familial glucocorticoid deficiency.53 Nonclassic patients may 
present as toddlers or as late as adulthood, with insidious onset of glucocorticoid deficiency, 
hyperpigmentation and high ACTH (but mostly intact mineralocorticoid function). A wide 
variation in gonadal function has been reported ranging from hypergonadotropic 
hypogonadism to normal.48 Similarly, 46,XY nonclassic patients may have normal male genitalia 
and normal puberty or be born with atypical  genitalia.54 
 
Cholesterol side-chain cleavage enzyme (SCC) deficiency 
P450 cholesterol side chain cleavage enzyme (SCC) is the first and rate-limiting step in the 
steroidogenic pathway (Figure 2G), encoded by CYP11A1 (Table 1) and is clinically and 
biochemically identical to lipoid CAH (Table 2); however patients typically have atrophic 
adrenals and gonads.48 Less than 40 cases have been reported.  
Similar to nonclassic lipoid CAH, nonclassic SCC deficiency has been described with delayed 
adrenal insufficiency onset and variable gonadal effect, caused by mutations corresponding to 
7-30% of retained enzyme activity.55-58  
Since StAR and SCC deficiency are similar clinically and biochemically, DNA testing is the only 
definitive method to distinguish between the two, with StAR deficiency being more common. 
 
Diagnosis 
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 Neonatal screening for 21OH deficiency is performed by measuring 17OHP in dried blood spots 
on filter paper. Second-tier screening with LC-MS/MS can efficiently measure a panel of 
steroids; this has been used to successfully diagnose 11βOH deficiency,59 but the focus of 
neonatal screening remains the detection of 21OH deficiency.  Premature, stressed, or ill 
infants could have falsely elevated 17OHP; specificity is improved with gestational age 
stratification.60 Testing using 21-deoxycortisol, which is elevated in 21OH deficiency, might 
increase neonatal screening specificity.61 
If an infant has a positive neonatal screen or is clinically suspicious for CAH (i.e. ambiguous 
genitalia), confirmatory testing is indicated. Although a basal panel of LC-MS/MS steroids may 
be diagnostic, diagnosis often requires cosyntropin testing,20,62 and is based on a characteristic 
rise in adrenal hormone(s) preceding the enzymatic block (Table 2). It should be kept in mind 
that 17OHP may be elevated in other types of CAH, such as 11βOH or POR deficiency. An 
alternative approach is urinary steroid profiling, which illustrates the entire steroid 
metabolome.63 Additional testing and genotyping may be needed to confirm the diagnosis. 
Screening for 21OH deficiency after infancy relies on measuring early morning (before 8 am) 
17OHP. A level above 1,000 ng/dL (30 nmol/L)  is diagnostic for 21OH deficiency, although a 
random level of 10,000 ng/dL (303 nmol/L) or greater is commonly observed in the classic form 
(Table 2).20 A level of less than 200 ng/dL (6 nmol/L) usually excludes nonclassic CAH if 
measured during the follicular phase of a reproductive-age woman.64 Cosyntropin stimulation 
testing is often needed for diagnosis of the nonclassic form.  
The diagnosis of POR can be best made with a urinary steroid profile, revealing characteristic 
precursor accumulation that can be captured by steroid ratios32 while serum steroid analysis 
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often yields confusing results due to the overlapping effects of combined 17OH and 21OH 
deficiency.  Further criteria for urinary and serum metabolites have been suggested to diagnose 
POR prenatally or differentiate POR from 21OH deficiency.65,66  
 
Management of CAH 
Medical Treatment 
Glucocorticoid therapy 
The mainstay of treatment in the classic forms of CAH is chronic glucocorticoid therapy 
(Panel). Because of their growth suppressing effect, long-acting glucocorticoids are avoided in 
children, but sometimes used in adults.68 The goal is to optimize control of excess hormones, 
while replacing deficient hormones and avoiding the potential Cushingoid side effects of 
glucocorticoid therapy. Laboratory results should guide but not define management; clinical 
evaluation should always be considered.  
 
In general, higher doses of glucocorticoids are needed to achieve adequate suppression of 
hormone excess (i.e. androgens in the virilizing forms of CAH, classic 21OH, 11βOH; DOC in 
17OH deficiency), whereas lower replacement doses of glucocorticoids should suffice if all 
steroids are deficient.  Lower glucocorticoid doses may also be used in the nonclassic forms of 
CAH, if treatment is indicated.69  
For women planning to conceive, a glucocorticoid that does not reach the fetus and is 
inactivated by placental 11βHSD2, such as prednisone, prednisolone or hydrocortisone, is 
typically used and continued throughout pregnancy.  
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Patients with nonclassic CAH are treated according to symptomatology.  Children with 
nonclassic 21OH deficiency should be treated if they have progressive signs and symptoms of 
virilization with advanced skeletal maturation.  Women with nonclassic CAH with signs of 
androgen excess can often be successfully treated with oral contraceptive, if needed in 
combination with spironolactone. Glucocorticoid therapy is used for female infertility in 
nonclassic 21OH deficiency and has been reported to reduce miscarriage rate when taken 
throughout pregnancy.70,71   
 
Mineralocorticoid replacement 
Mineralocorticoid, in the form of fludrocortisone, is given to achieve a plasma renin activity in 
the normal range in the salt-wasting forms of CAH (Panel)20. The dose is independent of body 
size, although higher doses are usually needed during the first 6 months of life due to neonatal 
physiological mineralocorticoid resistance. Infants also require salt supplementation. Although 
patients with SV 21OH deficiency have some aldosterone production, relative aldosterone 
insufficiency exists and fludrocortisone is recommended as it allows for glucocorticoid 
reduction leading to improved height outcomes.72   
 
Glucocorticoid stress dosing 
Patients receiving glucocorticoid treatment, including those with the nonclassic form, need to 
be educated on adrenal crisis prevention and increasing glucocorticoid dose during intercurrent 
illness (Panel). Intramuscular, subcutaneous, or intravenous hydrocortisone should be given 
when oral intake is not possible, and stress dose coverage is identical to that recommended in 
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primary adrenal insufficiency.67 Patients with classic 21OH deficiency also have epinephrine 
deficiency, due to abnormal adrenomedullary formation;73 this places patients at risk for 
hypoglycemia, especially when fasting, or during acute illness.  Adrenomedullary function has 
not been studied in the rarer forms of CAH. 
Patients with nonclassic CAH may have suboptimal cortisol response on stimulation testing 
(< 18 ug/dl).  If asymptomatic, daily glucocorticoid is not indicated, but glucocorticoid stress 
coverage should be employed during serious illness or major surgery.  
 
Sex steroids  
Sex steroid replacement is started around the time of physiological puberty in 17OH deficiency, 
3HSD deficiency, lipoid CAH, SCC deficiency, and POR (as needed).  Androgen (males) and 
estrogen (females), with progestin to induce cyclical bleeding (if uterus present) are advanced 
slowly to adult regimens (Panel).  
` 
Anti-hypertensive  
In both 11 βOH and 17OH deficiency, glucocorticoid therapy is often sufficient to control 
hypertension by suppressing DOC. However, because high dose glucocorticoid therapy and 
complete suppression of the HPA axis should be avoided, DOC is not fully suppressed and many 
patients eventually become hypertensive. A mineralocorticoid receptor antagonist or calcium 
channel blocker can be used31,74 (Panel). 
 
Controversial Therapies 
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Genital Surgery 
Surgery for disorders of sex development (DSD) is a complex issue that has generated much 
controversy.  Historically, surgeons have recommended surgery based on genital appearance 
and fertility potential. In the past two decades, some advocacy groups and physicians have 
recommended delaying surgery so that patients can participate in the decision regarding 
surgical intervention.  Conversely, others have expressed concern regarding the lack of 
outcome data and psychosocial stress of not doing early surgery.  Most importantly, the family 
should always be educated on the pros and cons of having and not having surgery. An 
interdisciplinary team of specialists is often required to navigate the decision making process.75  
An international group of experts in CAH appointed by the Endocrine Society to develop 
Clinical Practice Guidelines for CAH due to 21OH deficiency concluded that surgery be 
considered for significantly virilized 46,XX CAH patients.20 Timing of the surgery is beyond the 
scope of this article but options include a one stage approach with neurovascular-sparing 
clitoroplasty, labioplasty, and  vaginoplasty being done simultaneously in infancy (norm in many 
countries including US and UK), waiting until puberty for any surgery, and performing 
labioplasty and clitoroplasty in infancy with vaginoplasty delayed until puberty.  Most CAH 
patients with 21OH deficiency prefer early surgery.76 Although in utero exposure to androgen 
has been shown to affect behavior with male typical behavior patterns commonly seen in 
classic 46,XX CAH patients, gender dysphoria is extremely rare and the recommended sex 
assignment of 46,XX DSD due to CAH is female.75 
The main challenge of surgery of the 46,XX virilized CAH patient remains the imperfect 
functional and cosmetic outcomes, including urinary incontinence, vaginal stenosis, and clitoral 
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pain, all of which can impact psychosocial and sexual well-being.77 Many of the new surgical 
approaches have not been present for long enough to assess outcomes. Patients should be 
referred to a specialist surgeon with DSD management experience.   
Surgical reconstruction of 46,XY atypical genital is complex. Chordee repair and surgery for 
distal hypospadias have high success rates, but proximal hypospadias repair is more challenging 
with higher complication and reoperation rates.  The main complications are urethral stricture, 
meatal stenosis, urethrocutaneous fistula and glans wings separation.78  
Early gonadal neoplastic changes were observed histologically as early as 1 year of age in a 
46,XY patient with classic lipoid CAH.79 Gonadectomy is recommended in severely affected 
46,XY patients being raised female, although risk of gonadal malignancy is unknown. 
 
Prenatal treatment 
For over 30 years, dexamethasone was offered to pregnant women at risk for having a child 
with classic virilizing CAH, aiming to suppress fetal androgen production and reduce virilization 
of an affected female. Dexamethasone, unlike hydrocortisone and prednisolone, crosses the 
placental barrier to the fetus without inactivation. Today, prenatal therapy is controversial, as 
only 1 of 8 fetuses will be an affected female when both parents are carriers. Long-term effects 
of in utero dexamethasone exposure are unknown with potential effects on the brain, behavior 
and cognition described.80-83  
Testing of fetal cells present in maternal circulation is being studied to avoid 46,XY treatment 
and initiate early treatment in affected 46,XX.84 Cell-free fetal DNA obtained from the mother’s 
plasma as early as 5 weeks gestation has correctly identified fetal CAH status in 14 families.85 
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Multiple international groups, including medical societies in the U.S. and Europe, have stated 
that prenatal therapy should only be considered in a research setting with full disclosure of the 
potential risks and benefits.20,86 The long-term effects of prenatal dexamethasone exposure 
requires further study but early non-invasive fetal DNA testing would potentially limit exposure 
to affected female fetuses. 
 
Bilateral Adrenalectomy 
  Bilateral adrenalectomy has been successfully used to treat female infertility with 
uncontrolled hyperandrogenism in 21OH deficiency87 and uncontrolled hypertension in 11βOH 
deficiency.88 Although follow-up of patients who have undergone adrenalectomy is overall 
positive, patients appear to be at increased risk of adrenal crisis and about one-third develop 
adrenal rest tissue if glucocorticoid dose is too low.89 Adrenalectomy should only be considered 
in patients who have failed all available medical interventions. 
 
Long-term Complications 
Glucocorticoid deficiency is characteristic of the severe forms of CAH, and is potentially life-
threatening.  A study in Sweden of 588 CAH patients compared to a national population-based 
registry revealed excess mortality in CAH because of adrenal crises,90 highlighting the 
importance of this aspect of the disease. A cross-sectional questionnaire-based study of 122 
CAH patients found the majority of adrenal crises occurred during infancy, with a second peak 
around late adolescence, and precipitated mainly by respiratory and gastro-intestinal 
infections.91  
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All children with CAH receiving glucocorticoid therapy are at risk for growth impairment and 
short stature.  This effect is dose-dependent, thus management is always aimed at treating with 
the lowest possible effective dose.  Alterations in sex steroid exposure can also influence 
height.   Late puberty may occur with the rare types of CAH associated with sex steroid 
deficiency, and can enhance adult height; vice versa, exposure to excess androgens and 
estrogens in the virilizing types of CAH can result in early puberty and early epiphyseal fusion 
(Figure 3B). A meta-analysis of 35 studies of classic 21OH deficiency showed an average final 
height of 1.38 standard deviations below the population norm.72 Whereas studies reveal an 
association between higher doses of hydrocortisone and shorter final height,92,93 earlier rather 
than later diagnosis and treatment has been associated with improved height outcomes, 
emphasizing the importance of prevention of hyperandrogenism.  
Cardiovascular disease risk factors commonly coexist with CAH.  In a cross-sectional UK study 
of classic 21OH deficient patients, over half of women were obese; and one-third had insulin 
resistance.94 In a Swedish cohort of 588 CAH patients, there was a higher frequency of 
hypertension, hyperlipidemia, diabetes, and venous thromboembolism compared to controls.95 
Long term glucocorticoid exposure, particularly higher doses for achievement of tight 
control, is a main risk factor for compromising bone health.  Studies over the past two decades 
show evidence of lower BMD in patients with 21OH deficiency as compared to controls, with 
the prevalence of low BMD (osteoporosis or osteopenia) ranging from 37 to 81%,94,96-98 with 
some studies reporting increased fracture rate.96,99  
Both males and females with the hypogonadal forms of CAH suffer from infertility. However, 
successful pregnancy has been achieved in one woman with classic lipoid CAH with clomiphene 
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citrate stimulation followed by progesterone supplementation.100 In vitro fertilization and 
transfer of cryopreserved embryos has successfully resulted in a live birth in lipoid CAH and 
17OH deficiency.101,102 Patients with POR, StAR, and CYP17A1 mutations may also have ovarian 
cysts and ovarian cyst torsion.103-105  
In the virilizing forms of CAH, excess adrenal sex steroids can lead to hypogonadotropic 
hypogonadism106,107 and increased progesterone can interfere with endometrial 
implantation.108,109 This may resolve with optimizing glucocorticoid management and 
suppression of follicular phase progesterone enhances the likelihood of ovulation and 
subsequent conception.110,111  
A main cause of male infertility in classic 21OH and 11βOH deficiency is adrenal rest tissue. 
Adrenal rest is thought to arise from aberrant cells of adrenocortical origin that migrate during 
fetal development along with the gonad after the adrenal and gonadal cells separate from the 
urogenital ridge. Adrenal rest is most commonly found in the rete testis (Figure 3C) and has 
been described in the ovaries and broad ligament.112,113 Testicular adrenal rest tissue (TART) 
causes obstructive azoospermia and deficient spermatogenesis. Low inhibin B levels reflect 
declining Sertoli cell function and can be used to monitor.106   The prevalence of TART is 
between 44-94% of men98,107,114,115 and 21-33% of boys98,116 with classic 21OH, and has also 
been reported in 11βOH and HSD3B2 deficiency,117-119 and rarely in nonclassic CAH.114 TART 
shrinkage and reversal of infertility are possible with glucocorticoid therapy;120 however the 
response is variable, because non-reversible fibrotic changes may occur over time.121    
 When unsuccessful, other modalities, such as intra-cytoplasmic sperm injection, could be 
considered.122 Testis-preserving surgery with TART resection has not restored fertility,123 but 
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can be done for orchialgia; simultaneous successful intraoperative sperm retrieval was recently 
reported.124 
 
Future Directions 
Alternative Androgen Synthesis Pathways  
The quest for new and improved biomarkers of disease severity or treatment response in CAH 
has included exploration of alternative androgen synthesis pathways. The so-called “backdoor” 
pathway, leads to the synthesis of DHT, without DHEA, androstenedione and testosterone as 
intermediates, originating directly from 17-hydroxyprogesterone (Figure 2A). This pathway has 
been implicated in the normal development of male genitalia54 and the prenatal virilization of 
affected females.16 Accumulation of 17-hydroxyprogesterone, as observed in 21OH and POR 
deficiency, increases the substrate flow to the “backdoor” pathway and subsequent studies 
have described increased alternative pathway metabolite excretion in patients with CAH due to 
POR 125 and 21OHD deficiency.126 
A further alternative androgen synthesis pathway involves the generation of 11-oxygenated 
C19 steroids in the adrenal cortex via CYP11B1 activity (Figure 2A),127 including, 11-
ketotestosterone and 11-keto-DHT, androgens that bind and activate the androgen 
receptor.128,129 11-oxygenated C19 steroids have been shown to be increased in CAH due to 
2OH deficiency 130,131 and exaggerated activity of both backdoor and 11-oxygenated C19 
pathways persists in treated patients, even if the classic androgen pathway activity is 
downregulated.130 
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Insights into these novel steroid markers will help to improve monitoring tools and define 
treatment targets. 
 
Genetic Advances 
Genetic studies of CAH have provided insight into the pathophysiology and subtle clinical 
aspects of the disease. Initially described in 1989,132 the TNXB gene which encodes the 
tenascin-X protein, a glycoprotein expressed in connective tissue, and its highly homologous 
pseudogene TNXA, flank CYP21A2 and its pseudogene CYP21A1P, respectively.  Chimeric genes 
which impair both the CYP21A2 and TNXB genes were found to explain an unusual observed 
phenotype of a connective tissue dysplasia consistent with hypermobility-type Ehlers Danlos 
syndrome in patients with 21OH deficiency.133,134 This novel syndrome, CAH-X, was prevalent in 
8.5 % of a cohort of 246 unrelated patients with 21OH deficiency.135  
Apart from CAH genes, other genes may modify steroid action, salt balance or androgen 
sensitivity and affect phenotype.136,137,138 
Genotyping is essential in confirming the carrier state, and is useful for genetic counseling or 
establishing the diagnosis of a patient who cannot undergo accurate hormonal testing due to 
glucocorticoid therapy. Genotyping may one day predict future outcomes and be efficacious in 
screening programs.139  
 
Novel Therapies 
Most of the adverse outcomes in patients with CAH are attributable to hormonal imbalances or 
treatment related comorbidities.  New and improved therapies are being developed that target 
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different aspects of the pathophysiology of CAH (Figure 4) and are being studied in classic 21OH 
deficiency.   
One approach is to replace cortisol in a physiological manner. Circadian cortisol replacement 
might achieve improved ACTH control and thus adrenal steroid secretion.  A modified-release 
oral hydrocortisone preparation, Chronocort®, was successful in achieving lower androgen 
levels while decreasing the hydrocortisone equivalent dose using a twice-daily regimen in a 
Phase 2 study of 16 patients with classic 21OH deficiency.140 A phase 3 study is currently 
underway (NCT02716818). Continuous subcutaneous hydrocortisone infusion via an insulin 
pump mimicking cortisol circadian rhythm, has similarly shown adequate ACTH suppression 
with lower total hydrocortisone dose compared to conventional treatment,139-142 and showed 
improved quality-of-life and fatigue in 8 patients with classic 21-OH deficiency.142 Long-standing 
comorbidities, such as insulin resistance and TART, remained mostly unchanged by 6 months, 
suggesting that early intervention is key and other approaches may be needed to treat well 
established comorbidities.   
As ACTH is the primary driver for excess steroid accumulation, strategies for reducing ACTH 
are under way.  A phase I, proof-of-principle study with a corticotropin-releasing factor type 1 
receptor antagonist, lowered morning ACTH or 17OHP in 6 of 8 females with classic 21-OH 
deficiency after a single dose.143 Future, multi-dose trials are needed.  
Pharmacologic blockade or inhibition of sex steroid synthesis in prepubertal children or 
women receiving sex hormone replacement would allow for lower dose glucocorticoid 
replacement in the virilizing forms of CAH.  This was studied in 28 prepubertal children with 
classic 21OH deficiency using an anti-androgen and aromatase-inhibitor in combination with 
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lower dose hydrocortisone and fludrocortisone, and was successful in normalizing growth over 
2 years.144  Pharmacologic inhibition of sex steroid synthesis was also tested in adult women 
with CAH receiving gonadal hormone replacement in a phase I, 6-day, dose-escalation study of 
Abiraterone acetate, a potent CYP17A1 inhibitor.145 Androstenedione normalized in 5 of 6 
women when abiraterone was added to physiologic doses of glucocorticoid and 
fludrocortisone, showing promising results.  Pharmacologic inhibition of sex steroid synthesis is 
also being studied with ATR-101 (NCT02804178), an inhibitor of acyl-coenzyme A: cholesterol-
O-acyltransferase 1, in a phase II study of classic 21-OH deficiency.146 
Adrenal enzyme inhibitors with adrenolytic properties may be useful in the treatment of 
CAH.  Mitotane, inhibits CYP11B1 and CYP11A1, and is adrenolytic with longer term use.  
Mitotane was successfully used to shrink TART and restore fertility in a 29-year-old male with 
classic 21OH deficiency.147 However, due to multiple toxicities of mitotane, the development of 
alternative adrenolytic therapies is needed.   
CAH is a monogenic disease, therefore gene therapy, with the use of cell-based and gene-
editing technologies, may be able to restore the defective steroidogenesis.148 Adrenal 
transplantation with novel technology using bovine adrenocortical cells has been successful in 
animal models of adrenal insufficiency.149 Future technological and genetic advances may 
enable us to one day cure CAH. 
 
Conclusion 
CAH is a group of rare diseases that if left undiagnosed and untreated would result in high 
morbidity and mortality.  The identification of alternative adrenal biomarkers has provided 
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insight into the origin and synthesis of steroid production and has the potential to alter disease 
management.  Decades of progress in understanding the genetics and pathophysiology of the 
various forms of CAH have led to a recent explosion in the investigation of new and improved 
therapies which promise to improve patient outcome.  
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Figure 1: Timeline denoting important discoveries in adrenal steroidogenesis, treatment 
landmarks and gene discovery of congenital adrenal hyperplasia 
 
Figure 2: Adrenal steroidogenesis pathways  
The CAH-causing genes are depicted in red.  Panel A shows the classical steroidogenesis 
pathway and alternative pathways leading to androgen production in the light yellow boxes. 
Panels B through G show the various forms of CAH and the impact of the specific impairment 
on the adrenal steroidogenic pathway. Light grey denotes deficient hormones in low levels due 
to the preceding block in steroid production. Dashed arrows denote indirect suppression of the 
subsequent hormone. Dashed lines across enzymes denote apparent enzyme deficiency. 
DHT = dihydrotestosterone; T= Testosterone. 
 
 
Figure 3: Adverse outcomes in congenital adrenal hyperplasia.  Panel A shows atypical 
genitalia with clitoromegaly and posterior labial fusion of a 46,XX infant with 21-hydroxylase 
deficiency.  Panel B is the growth chart of a female with classic 21-hydroxylase deficiency who 
experienced early puberty and early epiphyseal fusion of her bones due to excess adrenal sex 
steroids and obesity due to excess glucocorticoid therapy.  Both likely contributed to her adult 
short stature.  A right sided, lobulated echopenic focus measuring 2.7 x 1.0 x 1.1 cm consistent 
with testicular adrenal rest tissue is shown in Panel C. 
 
Figure 4: Novel and emerging treatments in the management of congenital adrenal 
hyperplasia targeting various aspects of the hypothalamic-pituitary-adrenal (HPA) axis and 
steroid production.  
 
Figure 1-4 Legends
Table 1- Genetic Causes and Clinical Features of the Various Forms of Congenital Adrenal Hyperplasia 
Type of CAH 21-hydroxylase 
deficiency 
 
11β-
hydroxylase 
deficiency 
   
17α-
hydroxylase/ 
17,20-lyase 
deficiency  
3β-hydroxy-
steroid 
dehydrogenas
e type 2 
deficiency 
P450 
Oxidoreduct
ase 
deficiency 
Lipoid 
adrenal 
hyperplasia 
Cholesterol 
side chain 
cleavage 
enzyme 
deficiency 
Genetic Cause 
(Affected 
Gene, 
OMIM#) 
CYP21A2 
#201910 
CYP11B1, 
#202010   
CYP17A1,  
#202110 
HSD3B2, 
#201810   
POR,  
#201750 
StAR, 
#600617 
CYP11A1, 
#118485 
Incidence Classic: 
1:10,000 to 
1:20,00022 
NC: 1:1,00023 
1:100,00028 
Caucasians,  
1:6,00029 
Moroccan 
Jews* 
NC: unknown 
1:50,00030 
Increased 
frequency in  
Brazil*30,31 
Rare Rare, 130 
cases from 
11 countries 
reported32 
Rare, mostly 
Japanese, 
Korean, and 
Palestinian 
populations 
33  
Rare, < 30 
patients, 
mostly from 
Eastern 
Turkey34 
Affected  
Organs 
Adrenal Adrenal Adrenal, 
gonads 
Adrenal, 
gonads 
Adrenal, 
gonads, liver, 
skeletal 
Adrenal, 
gonads 
Adrenal, 
gonads 
 DSD Classic: 46,XX 
NC: No 
Classic: 46,XX 
NC: No 
46,XY 
 
Classic: 46,XY, 
46, XX (rare) 
NC: No 
46,XX, 46,XY 
(variable) 
46,XY 
NC: 46,XY 
(variable) 
46,XY 
NC: 46,XY 
(variable) 
Salt-wasting 
 
Classic: Yes 
NC: No 
No No Yes No Classic:  yes 
NC: Minimal 
to none 
Classic:  yes 
NC: Minimal 
to none 
Hypertension  No Yes 
NC: variable 
Yes No Yes No No 
Postnatal 
Virilization  
Classic:  yes 
NC: yes 
Classic: Yes 
NC: Yes 
No Classic: 46,XX 
NC: 46,XX 
No No  No 
Sex Steroid No No  Yes Classic:  yes Yes Yes Yes 
Table 1
Deficiency NC: no  NC: variable NC: variable  
Other       ± Skeletal 
malformatio
ns  
± Maternal 
virilization 
  
*Due to presence of a founder mutation 
CAH=congenital adrenal hyperplasia; DSD=Disorder of Sex Development; NC=nonclassic, POR= P450 Oxidoreductase; StAR= 
Steroidogenic acute regulatory protein. 
 
 
 
Table 2 – Clinical Presentation and Biochemical Findings  
Type/ Enzyme Clinical Presentation Hormonal Profile Cosyntropin stimulation 
testing* 
 
Other testing 
21-hydroxylase 
deficiency 
   
  
Classic: atypical genitalia 
(46,XX), neonatal salt-
wasting (75%), virilization 
< 4 year old (46,XY) 
 
NC: Precocious pubarche, 
hirsutism, 
oligomenorrhea/ 
amenorrhea, female 
infertility  
↑: 17OHP, ↑21-
deoxycortisol, 
androstenedione, renin 
↓: cortisol, aldosterone  
17OHP > 1,000 ng/dL (30 
nmol/L) (several times 
higher for classic) 
NC: Early morning 
follicular phase 
17OHP< 200 ng/dL 
(< 6 nmol/L) 
usually excludes 
NC CAH 
11β-hydroxylase 
deficiency 
Classic: atypical genitalia 
(46,XX),  virilization < 4 
year old (46,XY),  
hypertension, 
hypokalemia 
 
NC: Precocious pubarche, 
hirsutism, 
oligomenorrhea/ 
amenorrhea, female 
infertility, ± hypertension 
↑: DOC, 11-deoxycortisol, 
androstenedione, 17OHP 
(mild) 
↓: Cortisol, aldosterone, 
corticosterone, renin 
 
11-deoxycortisol > 3 times 
the upper limit of normal 
(several times higher for 
classic) 
 
17α-
hydroxylase/17,20-
lyase deficiency 
Adolescent female with 
absence of 2’ sexual 
characteristics, 
↑: DOC, corticosterone 
(>4000ng/dL, 115 nmol/L), 
progesterone 
Poor response of 
17OHpregn and 17OHP  
 
 
Table 2
hypertension, 
hypokalemia. 
 
↓: cortisol, aldo, 17OH-
pregn, 17OHP, renin 
DHEA, androstenedione  
Elevated ratio of: 
DOC/cortisol, 
corticosterone/sex 
steroids  
 
3β-hydroxysteroid 
dehydrogenase type 2 
deficiency 
atypical genitalia (46,XX: 
rare, mild; 46,XY), 
neonatal salt-wasting 
 
NC: Precocious pubarche, 
hirsutism, oligomenorrhea/ 
amenorrhea (46,XX); 
atypical genitalia (46,XY: 
mild) 
↑: 17OH-pregn, DHEA, renin  
↓: Cortisol, aldosterone, 
progesterone, 17OHP, 
androstenedione, DOC, 11-
deoxycortisol 
17OHpregn > 5000 ng/dL 
(150 nmol/L)  
 
Elevated Ratios 
pregnenolone / 
progesterone,  
17OHpregn /17OHP  
Poor testosterone 
response hCG 
stimulation in 
infancy 
P450 Oxidoreductase 
deficiency  
Atypical genitalia, 
± skeletal manifestation 
(Antley-Bixler), 
± maternal virilization 
↑: pregnenolone, 
progesterone, 17OHP, 
DOC, corticosterone, 
↓: DHEA, androstenedione 
 
Variable (normal or low): 
cortisol, aldosterone.  
Variable 17OHP response, 
variable cortisol response 
(often inadequate) 
 
Urine steroid 
metabolite profile 
shows 
characteristic 
diagnostic profile  
 
Lipoid adrenal 
hyperplasia or 
SCC enzyme deficiency 
Classic: Female genitalia, 
neonatal salt-wasting  
 
NC: Adrenal insufficiency 
(2 years- adulthood), 
variable gonadal function, 
variable genitalia (46,XY: 
mild) 
↑: renin  
↓: All steroids  
 
NC: variable  
Minimal to no response 
 
 
NC: variable response, 
↓cortisol common 
Classic: Minimal 
response hCG 
stimulation 
 
Genetic testing 
needed to 
differentiate lipoid 
CAH and SCC 
deficiency 
*Administration of standard dose of 250 mcg cosyntropin (in very low birth weight infants the dose may be reduced to 0.125mg), 
concomitant measurement of 17OHP, cortisol, DOC, 11-DOC, 17-OH-pregnenelone, DHEA, and androstenedione at baseline and 
60 minutes distinguishes 21OH deficiency from other rarer forms of CAH. 
NC=nonclassic. 17OHP=17-hydroxyprogesterone. DHEA=dehydroepiandrosterone. DOC=deoxycorticosterone. 17OHpregn=17-
hydroxypregnenolone. hCG=human chorionic gonadotropin. SCC=side chain cleavage. 
 
Panel: Management of Congenital Adrenal Hyperplasia 
Glucocorticoid Replacement 
 Needed in classic forms of CAH, 
variable use in NC forms and PORD 
 Children: hydrocortisone (8-15 
mg/m2/day) divided into 3 doses, 
using the lowest dose allowing 
normal growth while controlling 
adrenal steroids  
 Adolescents and adults: 
hydrocortisone 2-3 times daily or 
longer-acting20,67 glucocorticoids, 
such as prednisone (5-7.5 mg/day; 
1-2 times daily), prednisolone (3-7 
mg/day; 1-2 times daily) or 
dexamethasone (0.25-0.5 mg/day; 
once daily) 
 Monitor for over-replacement: 
weight gain, central obesity, striae, 
stunted growth (children), declining 
bone mineral density  
 Monitor for under-replacement: 
weight loss, fatigue, 
hyperandrogenism (21OH and 
11βOH deficiency), hypertension 
(11βOH, 17OH deficiency and in 
adult POR deficiency patients) 
 In women, monitor for cycle 
regulatory and, if appropriate, 
anovulation 
 In males, monitor for testicular 
adrenal rest tissue (TART) employing 
testicular ultrasound from 
adolescence onward; if positive, 
then offer sperm count and motility 
assessment and counsel re the 
possibility of cryopreservation of 
semen  
 
Stress Dosing 
 Needed if patient receiving 
glucocorticoid therapy or cortisol 
response to cosyntropin stimulation 
<18 g/dl (500 nmol/L) 
 Double or triple glucocorticoid 
during intercurrent illness (fever, 
gastrointestinal illness), surgery or 
trauma 
 Intramuscular or subcutaneous 
hydrocortisone if unable to take oral 
glucocorticoid (home regimen). 
Children 50 mg/m2; adults 100 mg 
IV bolus followed by 200 mg over 
24hours (hospital regimen)67 
 
Mineralocorticoid Replacement 
 Needed in salt-wasting forms of CAH  
 Fludrocortisone 50-300 mcg daily to 
achieve a plasma renin activity in 
the mid-normal range  
 First 6-12 months of life: sodium 
chloride 1-2 g (17-34 mEq) daily, 
divided and given with feeds 
 Monitor for over-replacement: 
hypertension, oedema, and 
suppressed plasma renin activity 
 Monitor for under-replacement: 
salt-craving, orthostatic 
hypotension, elevated plasma renin 
activity 
 Encourage salt intake during hot 
weather and conditions that promote 
excessive sweating. Consider seasonal 
adjustment of fludrocortisone dose in 
countries with very hot summers. 
  
Sex Steroid Replacement 
 Needed in CAH forms that result in 
sex steroid deficiency 
 For pubertal females, oral estradiol 
(0.5 mg per day advanced to 1-2 mg 
per day); or transdermal (25 mcg per 
day advanced to 75-100 mcg per 
day) over 2-3 years; progesterone, 
Panel
added following 2 years of estrogen 
monotherapy or when breakthrough 
bleeding occurs, 100-200 mg per 
day, or medroxyprogesterone 
acetate 5-10 mg per day, or 
norethindrone acetate 2.5-5 mg per 
day, for 5-10 days, in women with 
intact uterus31  
 For pubertal males, intramuscular 
testosterone (50 mg per monthly 
titrated to about 200 every 2 weeks) 
or transdermal testosterone 
(titrated to 25-100g per day)31  
 
Anti-hypertensive treatment 
 Needed if glucocorticoid 
unsuccessful in treating 
hypertension in 11βOH and 17OH 
deficiency 
 spironolactone 50-200 mg per day in 
1 or 2 divided doses or eplerenone 
50-100 mg per day 
 Calcium-channel blockers, such as 
amlodipine, 2.5-10 mg per day, may 
be used 
 
Anti-androgen treatment 
 Oral contraceptives ± spironolactone 
to control hirsutism, amenorrhea in 
nonclassic 21OH and 11βOH 
deficiency 
 
Infertility 
 Initiate glucocorticoid for nonclassic 
forms 21OH and 11βOH deficiency 
 Optimize glucocorticoid therapy 
with suppression of follicular phase 
progesterone (females) and 
shrinkage TART (males) for 21OH 
and 11βOH deficiency 
 Clomiphene citrate stimulation with 
progesterone supplementation for 
hypogonadal forms CAH 
 Consider In vitro fertilization 
(females), intra-cytoplasmic sperm 
injection (males) 
 
Pregnancy 
 If on glucocorticoid therapy, 
hydrocortisone, prednisone, or 
prednisolone can be used, 
dexamethasone should be avoided 
 Increase glucocorticoid dose by 20-
40%, particularly during third 
trimester67 
  Stress dosing for labor and delivery 
 
Additional Monitoring Requirements 
 Clinical evaluation frequently in first 
year of life, every 4-6 months for 
growing child and yearly for adults 
 Patients on glucocorticoid 
replacement should wear 
emergency bracelet/card, receive 
sick day rule education, and carry 
emergency hydrocortisone kit 
 Screening for psychological and 
sexual health issues and late-onset 
complications of genital surgery, if 
indicated 
 Age-appropriate vitamin D and 
calcium intake and bone mineral 
density screening during early 
adulthood 
 Orthopaedic management may be 
needed for PORD 
 
 
 
CAH=congenital adrenal hyperplasia. NC=nonclassic. PORD= P450 Oxidoreductase deficiency.  
21OH=12-hydroxylase. 11βOH=11β-hydroxylase. 17OH=17-hydroxylase. TART=testicular adrenal 
rest tissue.  
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